Overview

NCI Definition: A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor). It is a tumor that differentiates along the lines of interstitial cells of Cajal. Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor. However, many patients still experience recurrence. Conventional chemotherapy and radiation therapy have been of limited value. A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases. [1]

Clinical Trials

There
are 45 clinical trials
for gastrointestinal stromal tumor, of which 39
are
open and 6
are
completed or closed.
Of the
trials that contain
gastrointestinal stromal tumor as an inclusion criterion, 1 is early phase 1 (1 open), 9 are phase 1 (8 open), 7 are phase 1/phase 2 (7 open), 20 are phase 2 (16 open), and 8 are phase 3 (7 open).

Significant Genes in Gastrointestinal Stromal Tumor

ABL1
+

ABL1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ABL1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
ARID1A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
ATM status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATR
+

ATR is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
ATR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATRX
+

ATRX is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
ATRX status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BARD1
+

BARD1 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
BARD1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRAF
+

BRAF is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 3
are open and 0
are closed.
Of the
trials that contain
BRAF status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 2 (3 open) [3].

BRCA1
+

BRCA1 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
BRCA1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2
+

BRCA2 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
BRCA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
BRIP1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

C11ORF30
+

C11orf30 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
C11orf30 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
CCNE1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12
+

CDK12 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
CDK12 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CHEK1
+

CHEK1 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
CHEK1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CHEK2
+

CHEK2 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
CHEK2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

DDR2
+

DDR2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
DDR2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
EGFR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2
+

EPHA2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
EPHA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 1
is closed.
Of the
trials that contain
ERBB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERBB4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2
+

ERCC2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERCC2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC3
+

ERCC3 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERCC3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC4
+

ERCC4 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERCC4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC5
+

ERCC5 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERCC5 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC6
+

ERCC6 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
ERCC6 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCB
+

FANCB is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCC
+

FANCC is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCD2
+

FANCD2 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCD2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCE
+

FANCE is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCE status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCF
+

FANCF is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCF status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCG
+

FANCG is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCG status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCI
+

FANCI is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCI status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCL
+

FANCL is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCL status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCM
+

FANCM is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
FANCM status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FBXW7
+

FBXW7 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FBXW7 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FGFR1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2
+

FGFR2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FGFR2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

FH
+

FH is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 0
are open and 2
are closed.
Of the
trials that contain
FH status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

FLT1
+

FLT1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FLT1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FLT4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK
+

FRK is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
FRK status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1
+

HDAC1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
HDAC1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC2
+

HDAC2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
HDAC2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1
+

IDH1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 0
are open and 1
is closed.
Of the
trial that contains
IDH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2
+

IDH2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 0
are open and 1
is closed.
Of the
trial that contains
IDH2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
KDR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 14 clinical
trials
for gastrointestinal stromal tumor, of which 13
are open and 1
is closed.
Of the
trials that contain
KIT status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 4 are phase 3 (3 open) [3].

Sunitinib, imatinib, nilotinib, regorafenib, and sorafenib
have
evidence of efficacy in patients with KIT mutation in gastrointestinal stromal tumor [3].

KRAS
+

KRAS is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 1
is closed.
Of the
trials that contain
KRAS status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MAPK11
+

MAPK11 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MAPK11 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1
+

MCPH1 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
MCPH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MDM2
+

MDM2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MDM2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4
+

MDM4 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MDM4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1
+

MLF1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MLF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH1
+

MLH1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MLH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH3
+

MLH3 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MLH3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A
+

MRE11A is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
MRE11A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MSH2
+

MSH2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH3
+

MSH3 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH6
+

MSH6 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH6 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH
+

MUTYH is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
MUTYH status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC
+

MYC is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 1
is open and 1
is closed.
Of the
trials that contain
MYC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

NBN
+

NBN is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
NBN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 0
are open and 1
is closed.
Of the
trial that contains
NF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

NPM1
+

NPM1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
NPM1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2
+

PALB2 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
PALB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PARP1
+

PARP1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PARP1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP2
+

PARP2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PARP2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 15 clinical
trials
for gastrointestinal stromal tumor, of which 14
are open and 1
is closed.
Of the
trials that contain
PDGFRA status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 5 are phase 3 (4 open) [3].

Avapritinib, dasatinib, imatinib, and sunitinib
have
evidence of efficacy in patients with PDGFRA mutation in gastrointestinal stromal tumor [3].

PDGFRB
+

PDGFRB is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
PDGFRB status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [3].

PMS1
+

PMS1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PMS1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS2
+

PMS2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PMS2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE
+

POLE is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
POLE status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A
+

PPP2R1A is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PPP2R1A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A
+

PPP2R2A is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
PPP2R2A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
PTEN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
RAD50 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51
+

RAD51 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
RAD51 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B
+

RAD51B is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
RAD51B status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
RAD51C status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D
+

RAD51D is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
RAD51D status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L
+

RAD54L is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
RAD54L status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1
+

RAF1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
RAF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

RET
+

RET is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
RET status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHA is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 1
is open and 2
are closed.
Of the
trials that contain
SDHA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

SDHAF2
+

SDHAF2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
SDHAF2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHB is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 1
is open and 2
are closed.
Of the
trials that contain
SDHB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

SDHC
+

SDHC is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 1
is open and 2
are closed.
Of the
trials that contain
SDHC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

SDHD
+

SDHD is an inclusion eligibility criterion in 3 clinical
trials
for gastrointestinal stromal tumor, of which 1
is open and 2
are closed.
Of the
trials that contain
SDHD status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].

SLX4
+

SLX4 is an inclusion eligibility criterion in 2 clinical
trials
for gastrointestinal stromal tumor, of which 2
are open and 0
are closed.
Of the
trials that contain
SLX4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SMARCB1
+

SMARCB1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
SMARCB1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2
+

STAG2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
STAG2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11
+

STK11 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
STK11 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TEK
+

TEK is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
TEK status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
TP53 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2
+

TRNAK2 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
TRNAK2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA
+

VEGFA is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
VEGFA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB
+

VEGFB is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
VEGFB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC
+

VEGFC is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
VEGFC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1
+

XRCC1 is an inclusion eligibility criterion in 1 clinical
trial
for gastrointestinal stromal tumor, of which 1
is open and 0
are closed.
Of the
trial that contains
XRCC1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

GIST, Unknown primary GIST, Gastrointestinal Stromal Neoplasm

Parent(s)

Stromal Neoplasm

OncoTree Name

Gastrointestinal Stromal Tumor

OncoTree Code

GIST

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.